Cita APA

Krug, A., Vaddady, P., Railkar, R., Musser, B., Cote, J., Ederveen, A., . . . Kothare, P. (2017). Leveraging a Clinical Phase Ib Proof‐of‐Concept Study for the GPR40 Agonist MK‐8666 in Patients With Type 2 Diabetes for Model‐Informed Phase II Dose Selection. Clin Transl Sci.

Chicago Style Citation

Krug, AW, et al. "Leveraging a Clinical Phase Ib Proof‐of‐Concept Study for the GPR40 Agonist MK‐8666 in Patients With Type 2 Diabetes for Model‐Informed Phase II Dose Selection." Clin Transl Sci 2017.

Cita MLA

Krug, AW, et al. "Leveraging a Clinical Phase Ib Proof‐of‐Concept Study for the GPR40 Agonist MK‐8666 in Patients With Type 2 Diabetes for Model‐Informed Phase II Dose Selection." Clin Transl Sci 2017.